ASLAN Pharmaceuticals Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to...
Clinical Trial
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management...
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs
Oxford Biomedica Solutions signs agreement with new partner to deliver The Full Solution for their AAV programs Bedford, Massachusetts –...
SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases Proceeds to fund...
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models...
Axsome Therapeutics to Present at the Cowen 2nd Annual Novel Mechanisms in Neuropsychiatry Summit
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD
All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions...
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million...
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022
Tessa developing allogeneic “off-the-shelf” CD30-CAR EBVST cell therapy – TT11X – targeting relapsed or refractory CD30-positive lymphomasSINGAPORE, Sept. 14, 2022...
JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial
Landmark ALIGN-AR Pivotal IDE Study Intended to Evaluate Use of the Trilogy™ Heart Valve System in Treatment of High Surgical...
Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models
LIfT BioSciences announces its N-LIfT cell therapy shows tumour destruction across five different solid tumour types in PDX tumouroid models...
Nacuity Pharmaceuticals and Arctic Therapeutics Enter Licensing Agreement and Strategic Partnership to Develop NPI-001
Collaboration leverages Nacuity’s NPI-001 for the treatment of fatal rare disease HCCAA in IcelandFORT WORTH, Texas and REYKJAVIK, Iceland, Sept....
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Study has reached extended enrollment target of 160 patients Top-line data...
Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study
Three clinical sites are now fully open; final three sites expected to open imminentlyASHBURN, Va., Sept. 13, 2022 (GLOBE NEWSWIRE)...
ABVC Biopharma Announces Letter to Shareholders
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical...
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes
- Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory...
Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of...
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal...